Liraglutide + PYY<sub>3-36</sub> Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements

Liraglutide + PYY<sub>3-36</sub> Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements

Background: Treatment options for NAFLD are still limited. Bariatric surgery, such as Roux-en-Y gastric bypass (RYGB), has been shown to improve metabolic and histologic markers of NAFLD. Glucagon-like-peptide-1 (GLP-1) analogues lead to improvements in phase 2 clinical trials. We directly compared...

Full description

Bibliographic Details
Main Authors: Valentin Metzner, Gloria Herzog, Tobias Heckel, Thorsten Bischler, Julia Hasinger, Christoph Otto, Martin Fassnacht, Andreas Geier, Florian Seyfried, Ulrich Dischinger
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Journal of Clinical Medicine
Subjects:
liraglutide
GLP-1
peptide tyrosine tyrosine (PYY)
peptide tyrosine tyrosine 3-36 (PYY<sub>3-36</sub>)
RYGB
gastric bypass
Online Access:https://www.mdpi.com/2077-0383/11/3/753

Internet

https://www.mdpi.com/2077-0383/11/3/753

Similar Items